Nanobiotix (NBTX) financial statements

Healthcare · Biotechnology · Market cap $952M

Nanobiotix reported revenue of 33M EUR in fiscal 2025, up 37.7% a year over 7 years.

Net income was -24M EUR and the operating margin -33.2%, against -864.2% in 2018.

Free cash flow was -34M EUR.

The diluted share count rose 144% over the period (dilution).

Revenue and free cash flow

Fiscal years, $ billions (EUR).

-0.1-0.0-0.000.00.020182019202020212022202320242025RevenueFree cash flow
Embed this chart

Free to use in articles and newsletters with the source line. Paste this HTML:

Income statement

Fiscal years, in EUR, from Nanobiotix's 10-K filings with the SEC.

Fiscal year20182019202020212022202320242025
Revenue3M EUR3M EUR3M EUR3M EUR5M EUR36M EUR-7M EUR33M EUR
Research and development21M EUR30M EUR24M EUR30M EUR33M EUR38M EUR41M EUR23M EUR
Selling, general and admin13M EUR19M EUR15M EUR19M EUR18M EUR22M EUR21M EUR20M EUR
Operating income-30M EUR-47M EUR-36M EUR-53M EUR-47M EUR-27M EUR-68M EUR-11M EUR
Interest expense847,000 EUR4M EUR-5M EUR780,000 EUR14M EUR15M EUR7M EUR15M EUR
Pre-tax income-30M EUR-51M EUR-34M EUR-47M EUR-57M EUR-40M EUR-68M EUR-24M EUR
Income tax0 EUR3,000 EUR9,000 EUR5,000 EUR10,000 EUR120,000 EUR101,000 EUR3,000 EUR
Net income-30M EUR-51M EUR-34M EUR-47M EUR-57M EUR-40M EUR-68M EUR-24M EUR
EPS (diluted)-1.55 EUR-2.35 EUR-1.38 EUR-1.35 EUR-1.64 EUR-1.08 EUR-1.44 EUR-0.50 EUR
Diluted shares19.63B21.63B24.39B34.73B34.85B36.93B47.27B47.82B
Operating margin-864.2%-1841.0%-1450.2%-1986.4%-977.8%-74.0%951.1%-33.2%
Net margin-872.2%-2003.7%-1337.2%-1778.0%-1194.3%-109.6%947.5%-73.5%

Balance sheet

Fiscal years, in EUR, from Nanobiotix's 10-K filings with the SEC.

Fiscal year20182019202020212022202320242025
Cash and short-term investments36M EUR35M EUR119M EUR84M EUR41M EUR75M EUR50M EUR53M EUR
Receivables—11,000 EUR62,000 EUR0 EUR101,000 EUR905,000 EUR3M EUR2M EUR
Total current assets43M EUR46M EUR125M EUR93M EUR52M EUR87M EUR61M EUR63M EUR
Property, plant and equipment8M EUR9M EUR8M EUR8M EUR7M EUR6M EUR6M EUR5M EUR
Total assets52M EUR56M EUR134M EUR102M EUR60M EUR94M EUR67M EUR68M EUR
Total current liabilities12M EUR14M EUR19M EUR37M EUR38M EUR50M EUR59M EUR58M EUR
Total liabilities37M EUR58M EUR64M EUR75M EUR87M EUR96M EUR133M EUR152M EUR
Shareholders' equity14M EUR-2M EUR70M EUR27M EUR-27M EUR-2M EUR-66M EUR-84M EUR
Net debt-36M EUR-35M EUR-119M EUR-84M EUR-41M EUR-75M EUR-50M EUR-53M EUR

Cash flow

Fiscal years, in EUR, from Nanobiotix's 10-K filings with the SEC.

Fiscal year20182019202020212022202320242025
Operating cash flow-26M EUR-41M EUR-28M EUR-30M EUR-37M EUR-12M EUR-20M EUR-33M EUR
Capital spending506,000 EUR1M EUR107,000 EUR233,000 EUR93,000 EUR337,000 EUR848,000 EUR546,000 EUR
Free cash flow-26M EUR-43M EUR-28M EUR-30M EUR-37M EUR-13M EUR-20M EUR-34M EUR
Stock-based compensation2M EUR4M EUR3M EUR3M EUR3M EUR3M EUR4M EUR4M EUR
Net borrowing16M EUR14M EUR10M EUR-3M EUR-4M EUR-3M EUR-3M EUR39M EUR
Free cash flow margin-761.5%-1677.0%-1100.5%-1137.3%-778.8%-35.4%283.7%-104.2%
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for NBTX.
Open NBTX in Investingly

Questions

What was Nanobiotix's revenue in 2025?

33M EUR in fiscal 2025, from its 10-K filing.

How much free cash flow does Nanobiotix generate?

-34M EUR in fiscal 2025 (operating cash flow minus capital spending).

From Nanobiotix's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.